• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Genentech’s pre-filled syringe for diabetic retinopathy wins FDA nod

March 21, 2018 By Sarah Faulkner

Lucentis 0.3-mg pre-filled syringe from GenentechRoche‘s (OTC:RHHBY) Genentech announced today that the FDA approved its 0.3-mg pre-filled syringe as a new way to administer Lucentis to diabetic retinopathy patients.

The company’s drug is the only FDA-approved medicine indicated for the treatment of diabetic retinopathy. The 0.3-mg pre-filled syringe is the first device of its kind approved to deliver an anti-vascular endothelial growth factor agent to patients with diabetic retinopathy and diabetic macular edema.

“Diabetic retinopathy is a serious condition that affects millions of people in the U.S.,” Dr. Sandra Horning, chief medical officer & head of global product development at Genentech, said in prepared remarks. “Today’s approval of the Lucentis 0.3-mg pre-filled syringe reinforces our commitment to advancing therapy for those impacted by this vision-threatening disease.”

Physicians administering Lucentis using the 0.3-mg pre-filled syringe can simply snap off the syringe cap, attach an injection needle to the syringe and adjust the dose, according to Genentech.

The drug-device combo will be available in the second quarter of this year, the company reported.

The 0.5-mg pre-filled syringe for Lucentis was approved by the FDA in Oct. 2016 and is indicated to treat wet age-related macular degeneration, macular edema following retinal vein occlusion and myopic choroidal neovasculariztaion.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Pharmaceuticals, Regulatory/Compliance, Wall Street Beat Tagged With: Genentech, Roche

IN CASE YOU MISSED IT

  • Tandem Diabetes Care delivers 1 million insulin boluses using t:connect mobile app
  • Nuvo, Sheba Medical Center develop AI-powered gestational diabetes management platform
  • Verily’s Onduo, Sword Health collaborate on virtual diabetes care
  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS